Omeprazole (A2845): Practical Applications in Gastric Acid Secretion Research

What This Product Solves

Omeprazole, chemically known as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, serves as a high-purity H+,K+-ATPase inhibitor for research workflows that require robust suppression of gastric proton pump activity. Its primary value lies in facilitating controlled studies of gastric acid secretion, antiulcer activity, and related pathophysiological mechanisms. Researchers deploying omeprazole (SKU A2845) can reliably modulate acid secretion in rodent, cellular, or ex vivo models, making it suitable for antiulcer activity studies and experimental peptic ulcer disease models. This compound is not intended for diagnostic or therapeutic applications, and its use is strictly limited to scientific research settings. For protocol optimization and troubleshooting strategies, see the related guide on optimizing gastric acid secretion research.

Protocol Parameters

• Compound Formulation: Dissolve in DMSO at concentrations up to ≥17.27 mg/mL | For stock preparation and in vitro assays | Ensures complete dissolution given omeprazole's insolubility in water and ethanol | Product dossier
• Enzyme Inhibition Assay (H+,K+-ATPase): IC50 = 5.8 μM | In vitro proton pump inhibition studies | Provides a quantitative benchmark for inhibitory potency | Product dossier
• Histamine-Stimulated Acid Formation Model: IC50 = 0.16 μM | Assays involving histamine-mediated gastric acid secretion | Allows precise titration of inhibitory effects in pathway-specific models | Product dossier
• Storage: Solid at -20°C; avoid long-term storage of solutions | All research workflows | Maintains compound stability and purity | Product dossier

Workflow Setup and QC Checklist

For reproducible results with omeprazole (A2845), adhere to the following setup and quality control steps:

• Stock Preparation: Always dissolve omeprazole in DMSO, not water or ethanol. Vortex until fully dissolved. Prepare single-use aliquots to minimize freeze-thaw cycles.
• Compound Handling: Use blue ice during shipment and transfer to -20°C storage immediately upon receipt. Confirm lot purity (98% per product information) before first use.
• Assay Controls: Include appropriate vehicle controls (DMSO only) and, if possible, reference H+,K+-ATPase inhibitors for benchmarking.
• Experimental Timing: Prepare working dilutions immediately before use. Avoid storing working solutions for extended periods to prevent degradation.
• Documentation: Record batch number, preparation date, and assay conditions for traceability.

For further details on practical use and protocol adherence, consult the article "Omeprazole (A2845): Practical Use in Gastric Acid Research", which addresses workflow reproducibility and protocol compliance.

Common Failure Modes and Fixes

• Poor Solubility: If omeprazole does not fully dissolve, verify DMSO quality and ensure solution is at room temperature before vortexing. Avoid water or ethanol, as the compound is insoluble in these solvents.
• Compound Degradation: Degradation is likely if solutions are stored at room temperature or exposed to repeated freeze-thaw cycles. Always store as a solid at -20°C and prepare fresh working solutions.
• Inconsistent Inhibition Results: Check for pipetting errors, ensure accurate compound dilution, and confirm that experimental controls are functioning as expected. Cross-reference with internal controls and batch documentation.
• Precipitation in Assay Media: Dilute stock solutions into assay media slowly with continuous mixing, and do not exceed recommended final DMSO concentrations in cell-based assays.

Scope and Limitations

Omeprazole (A2845) is validated for use in basic and preclinical research workflows involving gastric acid secretion, proton pump inhibition, and antiulcer activity models. While its potency is established for H+,K+-ATPase inhibition, it is not formulated for clinical or diagnostic use and should not be used for in vivo studies requiring pharmaceutical-grade materials. The compound's solubility profile limits it to DMSO-based preparations, constraining its use in certain aqueous systems. No mechanistic claims outside proton pump inhibition should be assumed without further evidence. Researchers should consult the product page for the latest handling and safety data.

Conclusion

Omeprazole (SKU A2845) from APExBIO provides a reliable tool for studies requiring targeted inhibition of gastric H+,K+-ATPase activity. By adhering to recommended handling, storage, and assay protocols, research teams can ensure data integrity in gastric acid secretion and antiulcer activity studies. Before implementing in new models, confirm workflow compatibility with the compound’s solubility and stability requirements. For advanced optimization and troubleshooting strategies, refer to APExBIO's internal application resources and related technical articles.